|
PRKAR2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.18249965375128E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.85629997221326E-09 |
| Normal-vs-Stage2 |
3.457600E-03 |
| Normal-vs-Stage3 |
1.44390055467625E-10 |
| Normal-vs-Stage4 |
4.94090002245429E-09 |
| Stage1-vs-Stage2 |
1.149240E-01 |
| Stage1-vs-Stage3 |
1.764380E-01 |
| Stage1-vs-Stage4 |
1.134620E-01 |
| Stage2-vs-Stage3 |
3.071700E-02 |
| Stage2-vs-Stage4 |
2.074300E-02 |
| Stage3-vs-Stage4 |
7.130200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.40559802580742E-11 |
| Normal-vs-AfricanAmerican |
3.019500E-03 |
| Normal-vs-Asian |
6.62959998010137E-09 |
| Caucasian-vs-AfricanAmerican |
2.290400E-01 |
| Caucasian-vs-Asian |
1.875620E-01 |
| AfricanAmerican-vs-Asian |
3.551900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.46700002040734E-10 |
| Normal-vs-Female |
2.22509999314724E-09 |
| Male-vs-Female |
1.021580E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.70780000036319E-08 |
| Normal-vs-Age(41-60Yrs) |
3.89700050007491E-10 |
| Normal-vs-Age(61-80Yrs) |
2.12689999945503E-07 |
| Normal-vs-Age(81-100Yrs) |
1.539800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.032800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.687000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.412800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.625200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.461600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.864200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.520800E-03 |
| Classical-VS-Follicular |
3.079200E-01 |
| Classical-VS-Other |
3.802100E-02 |
| Classical-VS-Normal |
4.27950008763389E-10 |
| Tall-VS-Follicular |
5.716300E-03 |
| Tall-VS-Other |
1.842590E-01 |
| Tall-VS-Normal |
1.27720001241727E-09 |
| Follicular-VS-Other |
1.462140E-03 |
| Follicular-VS-Normal |
2.616800E-04 |
| Other-VS-Normal |
5.80809999983778E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.88769999631688E-08 |
| Normal-vs-N1 |
1.59239998964722E-09 |
| N0-vs-N1 |
4.101900E-02 |
|
|
